Drug Trial Radar · NCT04045327
Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock
Last checked: Nov 20, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jan 31, 2019
Primary completion
Sep 23, 2019
Study completion Sep 27, 2019
Sponsor
- Lead sponsor
- Pharmazz, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-III efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock. Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine) has been found to be an effective resuscitative agent in rat, rabbit and swine models of hemorrhagic shock, it decreased blood lactate, increased mean arterial pressure, cardiac output, and decreased mortality. An increase in cardiac output during resuscitation is mainly attributed to an increase in stroke volume. Centhaquine acts on the venous α2B-adrenergic receptors and enhances venous return to the heart, in addition, it produces arterial dilatation by acting on central α2A-adrenergic receptors to reduce sympathetic activity and systemic vascular resistance.
Conditions
- Hypovolemic Shock
Interventions
Normal saline + Standard TreatmentDrug
Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
Centhaquine + Standard TreatmentDrug
Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in systolic and diastolic blood pressureTime frame: 48 hours
- Change in blood lactate levelTime frame: 48 hours
- Change in base-deficitTime frame: 48 hours
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Jawahar Lal Nehru Medical College & Attached Hospitals
Ajmer, India
Radiant Superspeciality Hospital
Amravati, India
People Tree Hospitals
Bangalore, India
KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre
Belagavi, India
Shri Guru Ram Rai Institute of Medical & Health Sciences
Dehradun, India
Department of Surgery, GSVM Medical College
Kanpur, India
Institute of Postgraduate Medical Education & Research and SSKM Hospital
Kolkata, India
King George's Medical University
Lucknow, India
Christian Medical College & Hospital
Ludhiana, India
Sidhu Hospital Pvt. Ltd.
Ludhiana, India
Department of General Medicine, JSS Hospital
Mysuru, India
New Era Hospital & Research Institute
Nagpur, India
Rahate Surgical Hospital & ICU
Nagpur, India
Criticare Hospital & Research Institute
Nagpur, India
ACSR Government Medical College & Hospital
Nellore, India
Maulana Azad Medical College and associated Lok Nayak Hospital
New Delhi, India
Institute of Medical Sciences, Banaras Hindu University
Varanasi, India
Seven Star Hospital
Nagpur, Maha, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.